Page last updated: 2024-10-20

urea and Sarcoma, Synovial

urea has been researched along with Sarcoma, Synovial in 2 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Sarcoma, Synovial: A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)

Research Excerpts

ExcerptRelevanceReference
"Synovial sarcoma is a soft tissue sarcoma, the growth regulatory mechanisms of which are unknown."1.33Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. ( Aoyama, T; Ishibe, T; Katagiri, T; Nagayama, S; Nakamura, T; Nakamura, Y; Nakayama, T; Nishijo, K; Okamoto, T; Shibata, KR; Shima, Y; Toguchida, J, 2005)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Abe, K1
Yamamoto, N1
Domoto, T1
Bolidong, D1
Hayashi, K1
Takeuchi, A1
Miwa, S1
Igarashi, K1
Inatani, H1
Aoki, Y1
Higuchi, T1
Taniguchi, Y1
Yonezawa, H1
Araki, Y1
Aiba, H1
Minamoto, T1
Tsuchiya, H1
Ishibe, T1
Nakayama, T1
Okamoto, T1
Aoyama, T1
Nishijo, K1
Shibata, KR1
Shima, Y1
Nagayama, S1
Katagiri, T1
Nakamura, Y1
Nakamura, T1
Toguchida, J1

Other Studies

2 other studies available for urea and Sarcoma, Synovial

ArticleYear
Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
    Cancer science, 2020, Volume: 111, Issue:2

    Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyc

2020
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-01, Volume: 11, Issue:7

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation;

2005